Phase 3 Readout
PHVS: Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of
August 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- August 1, 2026
- Company
- Pharvaris N.V. (PHVS)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of
- Company
- Pharvaris N.V. (PHVS)
- Indication
- Hereditary Angioedema (HAE)